Roflumilast for asthma: Efficacy findings in placebo-controlled studies

Conclusion Together these studies show that roflumilast has potential as an effective anti-inflammatory therapy for the treatment of asthma. Additional beneficial effects are observed when given in combination with ICS, which warrant further investigation. All studies were funded by Takeda. Trial registration numbers available on ClinicalTrials.gov: NCT00073177, NCT00076076, NCT00163527.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research